CALC

SEC source: 0001209191-23-020677 · doc4.xml · derivative · entry 7

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,915

Underlying: Common Stock · 7,915 shares

Expires 2031-06-30

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F10 · price: Received in exchange for a stock option to acquire 274,848 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F9 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020677 · doc4.xml · derivative · entry 6

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,147

Underlying: Common Stock · 13,147 shares

Expires 2031-04-27

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F11 · price: Received in exchange for a stock option to acquire 456,522 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020677 · doc4.xml · derivative · entry 5

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,915

Underlying: Common Stock · 7,915 shares

Expires 2031-04-27

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F10 · price: Received in exchange for a stock option to acquire 274,848 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F9 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020677 · doc4.xml · derivative · entry 4

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,589

Underlying: Common Stock · 23,589 shares

Expires 2030-06-29

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F8 · price: Received in exchange for a stock option to acquire 819,064 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F7 · derivative.exercise_date: 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020677 · doc4.xml · derivative · entry 3

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,640

Underlying: Common Stock · 8,640 shares

Expires 2029-04-24

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F6 · price: Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F5 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020677 · doc4.xml · derivative · entry 2

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,777

Underlying: Common Stock · 22,777 shares

Expires 2028-08-01

F3 · price: Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020677 · doc4.xml · derivative · entry 1

Dunn Michael J. · CIK 0001968792 · President and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,761

Underlying: Common Stock · 11,761 shares

Expires 2024-10-01

F2 · price: Received in exchange for a stock option to acquire 408,402 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

F1 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 17

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 9,935

Underlying: Common Stock · 9,935 shares

Expires 2026-05-25

F22 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F13 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 16

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 9,935

Underlying: Common Stock · 9,935 shares

Expires 2026-02-22

F22 · price: Received in exchange for a stock option to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F13 · derivative.exercise_date: Immediately exercisable.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 15

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,342

Underlying: Common Stock · 12,342 shares

Expires 2023-03-19

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F21 · price: Received in exchange for a stock option to acquire 428,566 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F18 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 14

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,443

Underlying: Common Stock · 30,443 shares

Expires 2033-03-19

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F20 · price: Received in exchange for a stock option to acquire 1,057,071 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F18 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 13

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,717

Underlying: Common Stock · 1,717 shares

Expires 2033-03-19

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F19 · price: Received in exchange for a stock option to acquire 59,641 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F18 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 12

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,062

Underlying: Common Stock · 1,062 shares

Expires 2032-08-30

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F17 · price: Received in exchange for a stock option to acquire 36,905 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F13 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 11

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,030

Underlying: Common Stock · 2,030 shares

Expires 2032-08-30

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F16 · price: Received in exchange for a stock option to acquire 70,490 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F13 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 10

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,552

Underlying: Common Stock · 3,552 shares

Expires 2032-08-30

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F15 · price: Received in exchange for a stock option to acquire 123,357 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F13 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 9

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,964

Underlying: Common Stock · 13,964 shares

Expires 2031-06-30

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F12 · price: Received in exchange for a stock option to acquire 484,863 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F11 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 8

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,826

Underlying: Common Stock · 19,826 shares

Expires 2031-04-27

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F14 · price: Received in exchange for a stock option to acquire 688,404 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F13 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 7

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,964

Underlying: Common Stock · 13,964 shares

Expires 2031-04-27

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F12 · price: Received in exchange for a stock option to acquire 484,863 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F11 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 6

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,381

Underlying: Common Stock · 30,381 shares

Expires 2030-06-29

F9 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.

F10 · price: Received in exchange for a stock option to acquire 1,054,921 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F8 · derivative.exercise_date: 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 5

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,173

Underlying: Common Stock · 76,173 shares

Expires 2030-01-23

F7 · price: Received in exchange for a stock option to acquire 2,644,900 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F5 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020676 · doc4.xml · derivative · entry 4

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,232

Underlying: Common Stock · 11,232 shares

Expires 2029-04-24

F6 · price: Received in exchange for a stock option to acquire 390,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F5 · derivative.exercise_date: 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.

SEC source: 0001209191-23-020676 · doc4.xml · nonDerivative · entry 3

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV VI, LLC

Disclosed balance after: 316,109

F4 · price: Received in exchange for 10,975,977 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

SEC source: 0001209191-23-020676 · doc4.xml · nonDerivative · entry 2

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV V, LLC

Disclosed balance after: 66,228

F3 · price: Received in exchange for 2,299,564 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

SEC source: 0001209191-23-020676 · doc4.xml · nonDerivative · entry 1

Leheny A. Rachel · CIK 0001484729 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Valence Investments SPV IV, LLC

Disclosed balance after: 356,989

F1 · price: Received in exchange for an aggregate of 12,395,423 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.

F2 · ownership.nature: The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 27

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 167

Underlying: Common Stock · 167 shares

Expires 2026-06-25

F33 · price: Received in exchange for a warrant to purchase 5,775 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 26

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 113

Underlying: Common Stock · 113 shares

Expires 2026-03-04

F32 · price: Received in exchange for a warrant to purchase 3,915 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 25

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 840

Underlying: Common Stock · 840 shares

Expires 2026-06-25

F31 · price: Received in exchange for a warrant to purchase 29,139 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 24

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 569

Underlying: Common Stock · 569 shares

Expires 2026-03-04

F30 · price: Received in exchange for a warrant to purchase 19,754 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 23

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), LP

Disclosed balance after: 3,249

Underlying: Common Stock · 3,249 shares

Expires 2026-06-25

F29 · price: Received in exchange for a warrant to purchase 112,796 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 22

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), LP

Disclosed balance after: 2,203

Underlying: Common Stock · 2,203 shares

Expires 2026-03-04

F28 · price: Received in exchange for a warrant to purchase 76,470 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 21

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, LP

Disclosed balance after: 12,380

Underlying: Common Stock · 12,380 shares

Expires 2026-06-25

F27 · price: Received in exchange for a warrant to purchase 429,837 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 20

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, LP

Disclosed balance after: 8,393

Underlying: Common Stock · 8,393 shares

Expires 2026-02-22

F26 · price: Received in exchange for a warrant to purchase 291,407 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 19

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 183

Underlying: Common Stock · 183 shares

Expires 2026-06-25

F25 · price: Received in exchange for a warrant to purchase 6,343 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 18

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 237

Underlying: Common Stock · 237 shares

Expires 2026-03-04

F24 · price: Received in exchange for a warrant to purchase 8,203 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 17

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 15,403

Underlying: Common Stock · 15,403 shares

Expires 2026-06-25

F23 · price: Received in exchange for a warrant to purchase 534,815 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 16

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 6,852

Underlying: Common Stock · 6,852 shares

Expires 2026-02-22

F22 · price: Received in exchange for a warrant to purchase 237,911 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 15

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 1,910

Underlying: Common Stock · 1,910 shares

Expires 2027-02-28

F21 · price: Received in exchange for a warrant to purchase 66,305 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 14

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI, LP

Disclosed balance after: 2,685

Underlying: Common Stock · 2,685 shares

Expires 2026-06-25

F20 · price: Received in exchange for a warrant to purchase 93,225 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 13

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI, LP

Disclosed balance after: 16,539

Underlying: Common Stock · 16,539 shares

Expires 2026-02-22

F19 · price: Received in exchange for a warrant to purchase 574,296 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 12

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI, LP

Disclosed balance after: 2,672

Underlying: Common Stock · 2,672 shares

Expires 2027-02-28

F18 · price: Received in exchange for a warrant to purchase 92,748 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · derivative · entry 11

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,760

Underlying: Common Stock · 5,760 shares

Expires 2032-10-24

F17 · price: Received in exchange for a warrant to purchase 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.

F16 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 10

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Golden Triangle Ventures, LLC

Disclosed balance after: 8,176

F14 · price: Received in exchange for 283,866 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F15 · ownership.nature: The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 9

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VII

Disclosed balance after: 1,548

F13 · price: Received in exchange for 53,733 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 8

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII (Canada), L.P.

Disclosed balance after: 47,052

F12 · price: Received in exchange for 1,633,699 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 7

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII Annex Fund, L.P.

Disclosed balance after: 14,425

F10 · price: Received in exchange for 500,854 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F11 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 6

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures VII, L.P.

Disclosed balance after: 256,852

F8 · price: Received in exchange for 8,918,437 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F9 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 5

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling VI Limited Partnership

Disclosed balance after: 8,884

F7 · price: Received in exchange for 308,455 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 4

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling VI Beteligungs GmbH & Co KG

Disclosed balance after: 7,456

F6 · price: Received in exchange for 258,883 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 3

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Ventures Management VI

Disclosed balance after: 17,682

F5 · price: Received in exchange for 613,943 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-23-020684 · doc4.xml · nonDerivative · entry 2

MIDDLETON FRED A · CIK 0001267959 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sanderling Venture Partners VI Co-Investment Fund, L.P.

Disclosed balance after: 582,757

F3 · price: Received in exchange for 20,234,606 shares of the common stock of CalciMedica pursuant to the Merger Agreement.

F4 · ownership.nature: The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.